MedTrace Logo

Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases

NCT02803437 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 334

Last updated 2025-07-10

No results posted yet for this study

Summary

This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine clinical practice.

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY 88-8223)

Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-21
Primary Completion
2022-01-06
Completion
2024-12-18

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02803437 on ClinicalTrials.gov